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Abstract.
Background: Adipose tissue dysfunction has been implicated in the pathophysiology of Alzheimer’s disease. However, the
involvement of adipokines, particularly adiponectin, remains unclear.
Objective: To compare serum and cerebrospinal fluid (CSF) levels of adiponectin, leptin and leptin-to-adiponectin ratio in
patients within the spectrum of Alzheimer’s disease and evaluate their relationship with classical biomarkers and their value
as markers of progression.
Methods: Amnestic mild cognitive impairment (MCI, n = 71) and Alzheimer’s dementia (AD, n = 53) subjects were con-
secutively recruited for serum and CSF adiponectin and leptin determination using an analytically validated commercial
enzyme-linked immunosorbent assay (ELISA). Correlations were explored using adjusted Spearman’s correlation coeffi-
cients. A logistic regression model and ROC analysis were performed to evaluate the staging predictive value of adipokines.
Results: Serum adiponectin was 33% higher in AD when compared to MCI patients. Adiponectin CSF levels, similar in both
groups, were positively correlated with A42 and cognitive function, though only in women. The area under the ROC curve
was 0.673 (95%CI:0.57-0.78) for serum adiponectin as predictor of dementia stage and the cut-off 10.85 g/ml maximized
the sum of specificity (87%) and sensitivity (44%).
Conclusion: Although longitudinal studies are required, we hypothesize that higher serum adiponectin in AD patients
constitutes a strategy to compensate possible central signaling defects. In addition, adiponectin might be specifically assigned
to neuroprotective functions in women and eventually involved in the female-biased incidence of Alzheimer’s disease.
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INTRODUCTION
In the last two decades, undeniable epidemio-
logical evidence has emerged indicating middle-age
obesity as a risk factor for Alzheimer’s disease [1].
Nevertheless, the pathophysiological mechanisms
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implicated are only scarcely disclosed. It is already
recognized that adipose tissue dysfunction con-
tributes to cerebrovascular disease which in turn
promotes and may even precede neurodegeneration
[2]. But on the other hand, several studies have
highlighted vascular-independent contributions of
obesity to Alzheimer’s disease, particularly through
adipokine-mediated effects on the central nervous
system (CNS) [3, 4]. It is unclear though to what
extent adipokines may influence cerebral structure
and function and which mechanisms are involved.
Adipokines are proteins mainly secreted by the white
adipose tissue that are involved in important physi-
ological functions such as regulation of appetite and
energy expenditure, glucose homeostasis, inflamma-
tion, and endothelial function [5–7]. First described
in the 1990 s, adipokines have already proved their
clinical relevance as biomarkers of adipose tissue
dysfunction and its related disorders [8, 9]. More
recently, adipokine’s neuroprotective actions and
their specific beneficial effects on memory have also
been reported. Leptin is able to enhance hippocam-
pal long-term potentiation and synaptic plasticity,
as well as to promote non-amyloidogenic process-
ing of amyloid- protein precursor and prevent
tau hyperphosphorylation [10]. On the contrary, a
beneficial role of adiponectin in Alzheimer’s dis-
ease natural history is still controversial, in spite of
its recognized insulin-sensitizing, anti-inflammatory,
anti-apoptotic, and anti-atherosclerotic properties
[11] as well as recent reports of its capacity to promote
dendritic growth, arborization, and spinogenesis in
mature dentate gyrus neurons [12]. Besides, there is
no published study addressing leptin-to-adiponectin
ratio (LAR) alterations in this disease or its asso-
ciation with biomarkers. Although serum LAR is
recognized as a more reliable marker of adipose tis-
sue dysfunction and of its metabolic effects than
adipokine serum levels separately [13, 14], there
is no evidence of its clinical relevance when mea-
sured in the cerebrospinal fluid (CSF). Therefore, this
study aims to explore the role of the two most abun-
dant circulating adipokines and their ratio in adipose
tissue-brain crosstalks in this disease context. It eval-
uates serum and CSF levels of adiponectin, leptin,
and LAR in patients with amnestic mild cognitive
impairment (MCI or prodromal phase) and mild-
to-moderate Alzheimer’s dementia (AD). It further
explores correlations between adipokine levels with
CSF and imaging biomarkers of the disease, as well as
gender differences that may contribute to the female-
biased incidence of Alzheimer’s disease.
MATERIALS AND METHODS
Participants and clinical evaluation
The study was conducted in a group of 124
subjects consecutively recruited at the Dementia
outpatient Clinic of Centro Hospitalar e Univer-
sitário de Coimbra (CHUC). They were extensively
characterized until a final probable diagnosis of an
Alzheimer’s disease spectrum disorder. We included
53 patients with a probable diagnosis of dementia due
to Alzheimer’s disease (mild and moderate stages)
that we further refer as AD, and 71 patients with the
diagnosis of amnestic MCI. A group of healthy or
asymptomatic/pre-clinical individuals was not con-
sidered since performing a lumbar puncture in these
individuals would not be ethically acceptable, as is
also the case of patients in severe dementia stages
whose clinical benefit of CSF biomarker analysis
is minimal. At baseline, patients and an informant
underwent a structured clinical interview conducted
by a neurologist. It included a detailed description of
complaints, with special focus on time course and
leading symptoms. Handedness, past medical and
family history as well as drug history were also reg-
istered. A complete neurological examination was
performed to rule out non-Alzheimer’s disease causes
of cognitive decline and weight, height, waist and hip
circumferences were measured according to the rec-
ommendations of World Health Organization Expert
Consultation report [15]. Body mass index (BMI) was
calculated using the following formula: BMI = body
weight (kilograms)/height2 (meters). Patients also
underwent biochemical evaluation and brain imag-
ing (computed tomography and/or MRI) to exclude
other forms of dementia and most of them were also
studied with CSF biomarkers and APOE genotyp-
ing. Probable Alzheimer’s dementia was diagnosed
according to the Diagnostic and Statistical Manual
of Mental Disorders criteria [16], the National Insti-
tute of Neurological and Communicative Disorders
and Stroke–Alzheimer’s Disease and Related Dis-
orders (NINCDS–ADRDA) [17] and more recently
to National Institute on Aging and the Alzheimer’s
Association (NIAAS) revised criteria [18]. MCI
patients were selected according to Petersen’s crite-
ria [19] and the likelihood of underlying Alzheimer’s
disease pathophysiology was assumed based on CSF
biomarker profile and/or neuropsychological profile
consistent with amnestic syndrome of the hippocam-
pal type. Clinical Dementia Rating (CDR) [20, 21]
of 0.5, 1, and 2 as well as neuropsychological
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battery tests scores (described below) were indicative
of MCI, mild and moderate dementia, respec-
tively. All participants or respective caregivers gave
informed consent to participate and all the proce-
dures were conducted in accordance with the ethical
review board of the Centro Hospitalar e Universitário
de Coimbra (CHUC).
Neuropsychological evaluation
The neuropsychological protocol included a bat-
tery of tests composed by the Mini-Mental State
Examination (MMSE) Portuguese version [22,
23], the Montreal Cognitive Assessment (MoCA)
[24, 25] Portuguese version, and the Alzheimer
Disease Assessment Scale-Cognitive (ADAS-Cog)
Portuguese version [26, 27]. Assessment was per-
formed by experienced neuropsychologists who also
administered the Portuguese versions of the CDR for
global staging and the Geriatric Depression Scale
(GDS-30) [28, 29] to exclude major depression.
Peripheral blood and CSF collection and
determinations
Blood samples were collected for general meta-
bolic and adipokine determinations as well as for
APOE genotyping. The homeostatic model assess-
ment of insulin-resistance index (HOMA-IR) was
calculated as [(If)*(Gf)]/ 22.5, where (If) is the fasting
insulin level (mU/ml) and (Gf) is the fasting glucose
level (mmol/L). Serum cholesterol (total and high-
density lipoprotein - HDL), triglyceride and fasting
glycemia were determined using commercial kits
(Olympus-Diagnóstica, Produtos de Diagnóstico SA,
Portugal). Low-density lipoprotein (LDL) choles-
terol was calculated according to the Friedewald
equation [30]. Leptin, adiponectin, and insulin were
determined using Human Adiponectin and Leptin
ELISA Kit (DuoSet, R&D Systems) and Human
Insulin ELISA kit (Mercodia, Sweden), respectively.
APOE genotype was determined by PCR-restriction
fragment length polymorphisms (RFLP) assay after
DNA isolation from whole EDTA-blood using a com-
mercial kit (Roche Diagnostics GmbH, Manheim,
Germany). Regarding CSF, pre-analytical and ana-
lytical procedures were done in accordance with
previously proposed protocols [31]. CSF A42, total
tau (t-tau), and phosphorylated tau (p-tau181) were
measured separately by commercially available sand-
wich ELISA kits (Innotest, Innogenetics, Ghent,
Belgium), as previously described [32]. Leptin and
adiponectin CSF concentrations were also measured
by sandwich ELISA (DuoSet, R&D Systems).
MRI data collection
A sub-group of participants (36 MCI, 31 AD)
underwent MRI on a 3T Siemens Magnetom
Trio scanner (Erlangen, Germany), using a 12-
channel birdcage head coil. High-resolution 3D
T1- weighted magnetization-prepared rapid gradi-
ent echo (MP-RAGE) scans were collected per
participant, with parameters defined on the basis
of guidelines from the Alzheimer’s Disease Net-
work Initiative [33]. Structural MRI scans were
processed by the FreeSurfer 5.0.0 software package
(http://surfer.nmr.mgh.harvard.edu ) using fully auto-
mated methods which are elsewhere described [34,
35]. Briefly, for each participant, cortical thickness
was estimated at each point of the cortical mantle by
finding the shortest distance from the white matter
surface to the grey matter surface (and vice-versa) and
averaging those two values. The neocortex was par-
cellated into 32 gyral-based regions-of-interest (ROI)
in each hemisphere, and in addition non-neocortical
ROIs, such as hippocampus, were defined on the basis
of automated procedures. Total hippocampal volume
was calculated by summing up right and left hip-
pocampal volumes. For each participant, the accuracy
of the determination of the grey and white matter
surfaces and of each individual ROI was carefully
inspected by a trained neuroradiologist.
Statistical analysis
A power analysis was performed in Gpower
3.1.9.2, concerning the comparison between serum
adiponectin levels measured for AD and MCI groups.
The resulting power was 85.6%. Each quantita-
tive variable was assessed for normality resorting
to Shapiro-Wilk tests and graphical analysis. When
found to be normally distributed, they were described
by their mean and standard deviation. Otherwise,
the median, 25th and 75th percentiles were used
instead. Categorical variables were described in terms
of absolute and relative frequencies. Comparisons of
quantitative variables between categories were per-
formed with t-Student tests, whenever the normality
assumptions held, and with Mann-Whitney U tests
otherwise. The associations between pairs of cate-
gorical variables were assessed with chi-square tests,
whereas correlations between pairs of quantitative
variables were assessed by computing Spearman’s
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correlation coefficients. Partial Spearman correlation
coefficients were also computed to account for the
influence of covariables. The analysis was performed
in R version 3.3.2 and the plots in IBM SPSS Statistics
24. The level of significance adopted was 0.05.
RESULTS
Baseline characteristics and adipokine profile of
the study participants
Demographic, clinical, and genetic characteris-
tics of the study participants are listed in Table 1.
There were no significant differences between MCI
and AD patients regarding age, gender, education,
and percentage of APOE4 carriers. Anthropomet-
ric measurements as well as typical vascular risk
factors and co-morbid metabolic diseases were also
similar in both groups. As expected, MMSE and
MoCA mean-scores were lower and ADAS-Cog
scores were higher in the AD group (p < 0.001). Addi-
tional serum and CSF biochemical and biomarker
data are presented in Tables 2 and 3, respectively.
A significant difference in serum adiponectin levels
between AD and MCI patients was observed, with
the former attaining 33% higher levels (Fig. 1). On
the contrary, serum leptin and LAR were equiva-
lent in both groups as well as CSF levels of both
adipokines and LAR.
Serum adiponectin as a staging biomarker of
Alzheimer’s disease
A logistic regression model was performed where
the patient status (MCI or AD) was taken as the
dependent variable and the following independent
variables were considered: serum and CSF leptin,
serum and CSF adiponectin, and HOMA-IR. This
was done after verifying that the strengths of the cor-
relations between the independent variables would
not lead to concerns with co-linearity: in particular
the correlations between serum and CSF adiponectin
(r = 0.532, p = 0.044) and between serum and CSF
leptin (r = 0.532, p = 0.044), which were both mod-
erate. Out of the independent variables, only serum
adiponectin was found to significantly contribute
to the model. Applying backward elimination, only
this variable remained significant, which achieved
statistical significance: χ2(1) = 9.547, p = 0.002,
Nagelkerke R2 = 0.114. Finally, taking serum and
Table 1
Demographic, clinical, and genetic data of study participants, according to baseline diagnosis
MCI AD p
n = 71 n = 53
Age (y) 73 (67; 76) 75 (68; 80) 0.060
Age onset (y) 67.33 ± 8.30 68.53 ± 9.08 0.507
Female gender n (%) 48 (67.6%) 37 (69.8%) 0.794
Education (y) 4 (4; 6.75) 4 (4; 9) 0.620
ApoE 4 carrier n (%) 41 (61.2%) 23 (45.1%) 0.082
BMI 26.36 ± 3.71 25.24 ± 4.22 0.143
WC (cm) 96.39 ± 10.70 92.45 ± 11.93 0.083
HC (cm) 102 (96.25; 107) 100 (96; 103) 0.202
WHR 0.94 (0.89; 1.00) 0.91 (0.87; 0.96) 0.074
Hypertension n (%) 38 (54.3%) 19 (38%) 0.078
Type 2 DM n (%) 13 (18.6%) 13 (26%) 0.330
Dyslipidemia n (%) 45 (64.3%) 24 (48%) 0.075
Heart Failure n (%) 8 (11.4%) 2 (4%) 0.191
MetS1 n (%) 27 (38.6%) 13 (24.1%) 0.242
MMSE 27 (25; 29) 19 (15.75; 23.25) <0.001
ADAS-Cog 11 (7; 13) 21 (16; 27.25) <0.001
MoCA 19.04 ± 4.94 10.38 ± 4.89 <0.001
Data presented as mean ± standard deviation, median (1st quartile, 3rd quartile) or as number
(percentage) of patients, as applicable. The p-values (p) included in the table were obtained
with independent samples t-Student tests or Mann-Whitney U tests for quantitative variables
and with chi-square tests for qualitative variables. 1MetS defined according to the International
Diabetes Federation (IDF). AD, Alzheimer’s disease; ADAS-Cog, Alzheimer’s Disease Assess-
ment Scale-Cognitive subscale; ApoE 4, Apolipoprotein E allele 4; BMI, body mass index; DM,
diabetes mellitus; HC, hip circumference; MCI, mild cognitive impairment; MetS, metabolic
syndrome; MMSE, Mini-Mental State Examination; MoCA, Montreal Cognitive Assessment;
WC, waist circumference; WHR; waist-to-hip ratio.
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Table 2
Serum biochemical data of study participants, according to baseline diagnosis
MCI AD p
n = 71 n = 53
Fasting glycemia (mg/dl) 89 (83; 97.25) 92 (86; 105) 0.140
Fasting insulinemia (mU/L) 4.92 (3.68; 5.86) 5.10 (4.21; 7.02) 0.252
HOMA-IR 1.11 (0.84; 1.42) 1.23 (0.92; 1.77) 0.196
Total cholesterol (mg/dl) 196 (176; 238) 207 (187; 233) 0.354
LDL-cholesterol (mg/dl) 121 (99.2; 161.4) 137 (115.8; 155.2) 0.122
HDL-cholesterol (mg/dl) 53.08 ± 12.70 54.68 ± 11.81 0.524
Triglycerides (mg/dl) 109 (80; 140) 93.50 (73; 130.75) 0.235
CRP (mg/dl) 0.23 (0.11; 0.39) 0.20 (0.07; 0.38) 0.278
Adiponectin (g/ml) 6.52 (3.86; 9.44) 9.80 (6.03; 14.30) 0.002
Leptin (ng/ml) 9.97 (6.44; 21.79) 10.12 (6.64; 19.40) 0.698
LAR 1.87 (1.01; 4.27) 1.44 (0.71; 3.03) 0.142
Data presented as mean ± standard deviation or median (1st quartile; 3rd quartile), as applica-
ble. The p-values (p) included in the table were obtained with independent samples t-Student
tests or Mann-Whitney U tests, as applicable. AD, Alzheimer’s disease; CRP, C reactive pro-
tein; HDL, high-density cholesterol; HOMA-IR,: Homeostasis Model Assessment-Insulin
Resistance; LAR, leptin to adiponectin ratio; LDL, low-density cholesterol; MCI, mild
cognitive impairment.
Table 3
Cerebrospinal fluid biomarker and biochemical data of study participants, according to baseline diagnosis
MCI n AD n p
A42 (pg/mL) 703.99 ± 340.18 37 425.58 ± 162.31 32 <0.001
t-tau (pg/mL) 382.9 (228.2; 520.7) 37 615.75 (449.33; 817.68) 32 <0.001
p-tau (pg/mL) 46.60 (32.7; 64.6) 37 73 (55.075; 85.55) 32 <0.001
t-tau/A42 0.74 (0.31; 1.02) 37 1.33 (1.06; 2.50) 32 <0.001
A42/p-tau 12.30 (8.67; 27.71) 37 5.75 (4.08; 7.47) 32 <0.001
ATI 0.73 (0.52; 1.29) 37 0.41 (0.25; 0.54) 32 <0.001
Adiponectin (ng/ml) 2.57 (1.85; 4.26) 34 2.93 (1.80; 4.85) 22 0.656
Leptin (pg/ml) 163.07 (122.19; 227.29) 34 147.02 (98.58; 174.38) 22 0.135
LAR 63.63 (34.34; 121.19) 34 41.64 (27.28; 99.53) 22 0.235
Data presented as mean ± standard deviation or median (1st quartile; 3rd quartile), as applicable. The p-values
(p) included in the table were obtained with independent samples t-Student tests or Mann-Whitney U tests, as
applicable. A, amyloid-beta; AD, Alzheimer’s disease; ATI, Amyloid-Tau Index; LAR, leptin to adiponectin
ratio; MCI, mild cognitive impairment; t-tau, total tau; p-tau, phosphorylated tau.
CSF leptin, serum and CSF adiponectin as a starting
point and adding confounding variables to the logis-
tic regression (hypertension, type 2 diabetes mellitus,
dyslipidemia, heart failure) results in a statistical sig-
nificant model, χ2(8) = 1892, p < 0.001, Nagelkerke
R2 = 0.447. Serum adiponectin’s contribution to the
model is again statistically significant (p = 0.018),
with no other variable displaying statistically signif-
icant contributions. A ROC analysis was performed
to evaluate the predictive value of serum adiponectin,
with the 95% confidence interval for the area under
the curve (AUC) being [0.57, 0.78]. The cut-off
10.85 g/ml maximizes the sum of the specificity
and sensitivity, which are 87% and 44%, respectively
(Fig. 2).
Association between adipokines and core
Alzheimer’s disease biomarkers
Cerebrospinal fluid biomarkers
In MCI patients, no correlation was found between
the concentration of both adipokines and CSF A42,
t-tau, and p-tau. In the AD group, out of the three core
CSF biomarkers only t-tau was inversely correlated
with CSF leptin after adjustments for age, gender, and
BMI (ρ = –0.597, p = 0.026). Meanwhile, in female
patients (MCI and AD), we observed a strong posi-
tive correlation between CSF levels adiponectin and
A42, which remained significant after age and BMI
adjustments (ρ = 0.590, p = 0.002) (Supplementary
Table 1).
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Fig. 1. Serum and CSF concentrations of adiponectin and leptin among MCI and AD subjects. Box and Whisker plots represent median,
upper median, lower median and minimum to maximum range of the adipokine concentrations. Only serum adiponectin reached statistically
significant difference (p < 0.01) between the two groups.
Imaging biomarkers
No significant correlation was observed between
adipokine levels and MRI volumetric measures
of medial temporal lobe (MTL) structures in AD
and MCI patients. Furthermore, and based on the
fact that women with Alzheimer’s disease seem to
experience faster hippocampal atrophy [36], we per-
formed the same analysis in this subgroup, but did
not observe consistent correlations (Supplementary
Table 2).
Association between adipokines and
neuropsychological tests
The total scores of MMSE, MoCA, and ADAS-
Cog were not correlated with serum or CSF levels
of both adipokines. Only serum leptin demonstrated
a tendency to negatively correlate with MoCA and
ADAS-Cog scores in the whole cohort after gender,
Fig. 2. ROC curve for serum adiponectin as predictor of dementia
phase of AD. The reference line represents the ROC curve for a
statistical test with no discriminatory ability. The area under the
ROC curve was 0.673 (95%CI: 0.57–0.78) and cut-off level was
10.85 g/ml (sensitivity = 0.44; specificity = 0.87).
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age, education, and BMI adjustments. However,
in female patients both MoCA and ADAS-Cog
were strongly correlated with CSF adiponectin, in
the sense that higher concentration was associated
with better cognitive function (ρ = 0.611, p = 0.046
and ρ = –0.548, p = 0.028, respectively). In addi-
tion, MoCA scores were inversely correlated with
CSF leptin and CSF LAR (ρ = –0.641, p = 0.033 and
ρ = –0.627, p = 0.039, respectively) (Supplementary
Table 3).
DISCUSSION
The present study investigated the association
between adipose tissue and Alzheimer’s disease
focusing on the alterations in serum and CSF levels of
adiponectin and leptin. For that purpose, we consid-
ered prodromal (MCI) and mild to moderate dementia
phases of the disease. This study also aimed to clarify
the epidemiological link between mid-life obesity
and late-onset Alzheimer’s disease as well as its
gender incidence bias. It provides novel biomarker-
based evidence of the relationship between
adipokines and AD pathology and proposes a
blood-based staging biomarker.
Adipokine levels in MCI and AD patients
Leptin
Serum leptin levels have been extensively associ-
ated with cognitive function and risk of Alzheimer’s
disease [37]. However, results from several clinical
studies are somehow divergent and dependent on epi-
demiological factors such as age, gender, and race
[38]. Recent findings have shown that, despite lep-
tin’s recognized neuroprotective abilities, in some
circumstances central resistance develops with con-
sequent leptin signaling impairment, which seems
to be the case in obesity and Alzheimer’s disease
[39, 40]. Regardless of the fact that we did not find
any significant differences in serum and CSF lep-
tin levels between both groups, Bonda et al. (2014)
previously described higher CSF leptin in AD when
compared to MCI patients [40]. This could be par-
tially explained by the fact that, in opposition to
our mild to moderate stage AD cohort, the subjects
included in the later study were in the latest patholog-
ical stage of disease and a six-fold increase in CSF
leptin of Braak VI patients compared to Braak 0-V is
described.
Adiponectin
On the other hand, few clinical studies have incon-
sistently reported an association between adiponectin
and Alzheimer’s disease (for review, see [11]).
Waragai et al. (2016) recently described higher lev-
els of adiponectin in the serum of MCI and AD
patients when compared to controls, but no differ-
ences between the two former groups [41]. They
have also shown significantly lower CSF adiponectin
levels in AD patients compared to MCI and con-
trols, although evident scattered results in the AD
group suggest that CSF adiponectin levels may vary
according to the severity or pathological stage of
the disease. Overall, our results are in line with the
most recent reports since serum adiponectin was 33%
higher in AD when compared to MCI patients, albeit
no differences were observed in the CSF. A possi-
ble explanation for this finding is the exclusion of
severe cases in our AD cohort, which raises the possi-
bility that higher peripheral secretion of adiponectin
can maintain, for an undetermined period of time,
normal CSF levels in the initial stages of the dis-
ease. Together, these results suggest that a rise in
adiponectinemia may reflect an effort to compen-
sate central defective signaling, similarly to what
happens with leptin. Furthermore, we found that a
cut-off of 10.85 g/ml in adiponectinemia predicted
the diagnosis of AD (versus MCI diagnosis) with
87% specificity though with only 44% sensitivity.
Although this distinction does not entail considerable
practical importance once MCI versus AD diagnosis
rests mostly on clinical aspects, serum adiponectin
could be explored as a staging biomarker, i.e., it
could reflect disease progression. On the other hand, it
would also be interesting to evaluate its usefulness in
the differential diagnosis with other forms of demen-
tia. Until now, the work of Bossolasco et al. (2017)
was the only to show higher serum adiponectin in a
non-AD type of dementia (frontotemporal dementia
versus controls) [42]. Although these results coun-
teract the usefulness of adiponectinemia as marker
of AD, very few patients have been enrolled in this
study (7 FTD; 9 AD; 36 controls).
Adipokines and Alzheimer’s disease biomarkers
Leptin
In this study, we report a moderate negative corre-
lation between CSF leptin and t-tau in AD patients,
reinforcing the involvement of this adipokine in
tau metabolism. Noteworthy, these results oppose to
those presented by Maioli et al. (2015) [43]. Although
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Fig. 3. Hypothetical crosstalk between Alzheimer’s disease and adiponectin physiology.
it is recognized that leptin is capable of reducing tau
phosphorylation [44], no correlation was observed
between leptin levels and p-tau.
In contrast to previous reports [45, 46], we
observed no association between serum or CSF leptin
levels and MTL volumetric measures.
Adiponectin
In accordance to other studies [41, 47], our results
showed no correlation between serum levels of
adiponectin and Alzheimer’s disease classical CSF
biomarkers, and contrary to our expectations, CSF
levels of adiponectin were also unrelated to A42,
t-tau, and p-tau concentrations in MCI and AD
patients. Notably, when we separately studied female
patients, we observed a strong positive correlation
between CSF adiponectin and A42 suggesting that
higher CSF levels of this adipokine are associated
with less soluble A42, and eventually less aggre-
gates. Our results come into line with the study
conducted by Waragai et al. (2016), the first to
demonstrate a correlation between CSF adiponectin
and A42 as well as with p-tau in a heteroge-
neous cohort (controls, MCI and AD; n = 189) [41].
However, they have not performed any subgroup
analysis based on diagnosis, biomarker profile, or
gender, and no adjustments for possible confounders
such as age, gender, BMI, or APOE genotype. The
co-localization of adiponectin with neurofibrillary
tangles in the Alzheimer’s disease brain is also inter-
estingly described by the same authors, suggesting
possible direct effects of this adipokine on patholog-
ical hallmarks of the disease.
Regarding imaging biomarkers, we found no
robust correlation between CSF adiponectin concen-
tration and MTL volumetry in MCI or AD patients
neither in the female sub-group. To our knowledge,
Waragai et al. (2016) was the only to report an inverse
correlation between CSF adiponectin and hippocam-
pal volume (r = –0.291, p < 0.001) in a combined pool
of patients [41], whereas the Mayo Clinic Study of
Aging published opposing data [48].
Furthermore, CSF leptin-to-adiponectin ratio did
not represent an added value in the correlation study
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with Alzheimer’s disease biomarkers compared to
individual adipokine concentrations.
Finally, some limitations can be pointed to this
study and include: 1) sample size which may be
insufficient to establish epidemiological associa-
tions; 2) the absence of a pre-symptomatic group; and
3) technical impossibility to distinguish adiponectin
isoforms.
Conclusions
The present study demonstrates that patients in the
mild to moderate dementia phases of Alzheimer’s dis-
ease present higher levels of serum adiponectin when
compared to patients in its prodromal phase (MCI).
Thus, adiponectin should be studied in larger cohorts
to determine its usefulness as blood-based biomarker
of disease progression. This study further demon-
strates that higher CSF levels of this adipokine are
associated with higher CSF concentration of soluble
A42 and better cognition in female patients. It high-
lights the gender specific role that adiponectin may
assume in the crosstalk between the brain and adipose
tissue. In fact, it was already recognized that a gynoid-
like distribution of fat (more prone to be associated
with higher adiponectin levels) is associated with
better cognitive performance, particularly in older
women [49]. In our perspective, these findings indi-
cate that clinical and basic research on Alzheimer’s
disease should always include gender specific out-
comes. Furthermore, gender differences in adipose
tissue’s physiology and its complex CNS interactions
should be included in the list of potential contributors
to the female-biased AD incidence.
Although longitudinal and larger studies are
required, these findings suggest that an eleva-
tion in serum adiponectin in AD patients may
represent a homeostatic response to counterbal-
ance neurodegeneration, taking into consideration
its insulin-sensitizing, anti-inflammatory and anti-
apoptotic effects (Fig. 3). Furthermore, these findings
also suggest that adiponectin might be specifically
assigned to neuroprotective functions in women,
indicating that research on Alzheimer’s disease
pathophysiology should always include gender spe-
cific outcomes. Ultimately, is important to outline
that even with the approval of new drugs, effec-
tive and aggressive strategies for the prevention of
Alzheimer’s disease are imperative and a thorough
understanding of its modifiable risk factors, including
obesity, may have an important impact on reducing
the burden of this devastating disease.
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